BACKGROUND: Quantitative ultrasound (QUS) devices provide portable, easy-to-operate, low-cost options tor point-ot-care screening of bone mineral density (BMO). Community pharmacists should be aware of the precision, sensitivity, and specificity of these devices priorto theirpurchase. OBJECTIVE: Todetermine the precision, sensitivity, and specificity of the Achilles Express ultrasonometer compared with central dual-energy X-ray absorptiometry (cOXA) as well as its utility as a bone density screening device in the community pharmacy setting.
O steoporosis leads to significant morbidity and mortality, including 250000 hip fractures in women annually in the US.1 A minority (one-third) of these osteoporotic women are diagnosed and even fewer (14%) receive treatment. The diagnosis of osteoporosis involves physical assessment, identification of risk factors, and bone mineral density (HMO) testing. According to the World Health Organization, BMD is best expressed as a t-score, the number of standard deviations (SO) above or below the average bone density of young, healthy adults> Author information provided at the end of the text.
The gold standard for HMO assessment is central dualenergy X-ray absorptiometry (cDXA).1 Due to the high cost of and limited access to cDXA testing, alternative methods are available for use in the ambulatory care setting for point-of-care (POC) screening. These devices, including peripheral OXA and quantitative ultrasound (QUS), provide portable, easy-to-operate, low-cost screening options. 3 • s In previous studies, t-scores obtained from QUS devices have been shown to correlate significantly with cDXA.6.10 However, these correlations are modest and their discordance from the cDXA t-scores may be due to several factors, including the fact that measurements are obtained at different sites with varying rates of age-related bone loss,differences in the manufacturer's published normal referencepopulations,and the possibility that the devicesdo not measurethe samebone properties,"
Regardless of these differences, heel (os calcis) QUS measurements have been shownto predictosteoporosis-related fractures in women.P:" In one investigation, heel QUS predicted hip fracture in womenover 75 yearsof age as well as hip cDXA did," Data supporting the use of QUS to predict fracture risk in younger women are limited. However,low QUS values in women 45-75 years of age have predicted wrist and other osteoporosis-related fractures with a level of accuracy similarto that of cDXA. 12 In a large studyinvolving more than 200000 postmenopausal women over the age of 50 years, a variety of peripheral BMD devices predicted overall fracture risk."
Community pharmacies providea convenient setting for POC BMD testing. Studies have documented the impact of community pharmacy screening programs using either peripheral DXA or QUS POC devices.":" Peripheral DXA, whichrequires radiation to deliverresults, has created safety concerns, causing some states to impose regulatory restrictions regarding its use in commu.nity pharmacies. The Food and Drug Administration has approved QUS devices that providecommunity pharmacies with an alternative method to screen for low BMD. Community pharmacists should be aware of the precision, sensitivity, and specificityof various QUS devices prior to purchase; differences in such parameters can affectthe validity of obtained results and subsequent pharmacist recommendations for further patient follow-up. Of particular importance is the fact that the screening results do not provide a high rate of falsenegatives, a resultthat wouldgive a patientthe impression that she is at low fracture risk when, in fact, cDXA wouldreveal that she is at highrisk for fracture.
The Achilles + (Lunar Corp., Madison, WI) QUS device, which has been shownto correlate with cDXA of the hip (r = 0.80 femoral neck, p < 0.(01) and spine (r = 0.67 spine,p < 0.(01), requires a patient's foot to be submerged in a warm water bath,"To decrease testing time and increase operator convenience,the Achilles + was replaced by the AchillesExpress, which does not use a water bath. The Achilles Express determines a stiffness index (SI) that is expressed as a t-score to indicate the risk of osteoporotic fracture in postmenopausal women.The SI is comparable to BMD as measured by cDXA.20 Physicians can use the tscore in conjunction with other risk factors to assist in the diagnosis of osteoporosis in the same way that cDXA tscores can be used. 20 ,2t Although the manufacturerreports a strong correlationbetween the Achilles Express and the Achilles + (r =0.94), there is only one published abstract that directly compares the Achilles Express with cOXA. 22 Data from 8 patients with chronic kidney disease, who were on prolongedcorticosteroid therapy, identified a sig-nificant correlation between the dominant and nondominant heel Achilles Express QUS results and hip cOXA (r = 0.84 and r = 0.84, respectively; p < 0.01). However, no correlation existed between the dominantor nondominant heel resultsof the Achilles Express QUS and spinecOXA (r =0.61 and r =6.47, respectively; p > 0.1).
The AchillesExpress is commercially available for use in community pharmacies as a bone density screening tool. The objective of this study was to compare the precision, sensitivity, and specificityof the Achilles Express device withcOXA and determine its utility as a 'screening tool for low BMO. This investigation included 2 groups of subjects to determine the sensitivity and specificity of the device in women at minimal risk for low BMD (young, healthy) and womenat higherrisk (postmenopausal).
Methods
This study was approved by the institutionalreview board and the Radioisotope and Radiation SafetyCommittee of AlbanyMedical College.Usinga board-approved flyer, subjects were recruited from the Albany College of Pharmacy faculty and staff and from an investigator's clinical practice site. Healthy women between the ages of 25 and 35 years wereconsidered eligiblefor inclusion in Group I if they were not pregnantand not taking any drugs known to affect BMD (eg, bisphosphonates,calcitonin,parathyroid hormone.corticosteroids). Women 45 yearsof age or older wereconsidered eligible for inclusion in Group2 if they were postmenopausal (defined as absence of menses for> I yor surgical menopause). There were no drug exclusion criteriain Group 2. The criteria for subjectrecruitment and targetenrollment numbers (25 in Group 1,50 in Group 2) were chosen to replicatepreviously published research involvingQUS devices," White women were included in this studybecause the QUS deviceutilized population data from whitewomen to report t-andz-scores,"
Recruited subjects werereferred to a private endocrinology practice to schedule appointments for cDXAand QUS BMD assessments. Afterinformed consent was obtained, demographic information and history (height,weight,dominanthand,medications, medical history) werecollected.Urinepregnancy testswereconducted in Group I subjects priorto thecDXAtest.One certified DXAtechnician performed all BMDassessmentsof the nondominant wrist and hip (neck.trochanter) and the spine (L1-lA) usingthe Delphia SL QDRseries fanbeam device (Hologic Inc., Bedford, MA) withall t-scores recorded. Osteopenia (t-score lessthan-1 andgreaterthan-25) andosteoporosis (t-score -2.5 or less)weredefined according to diagnostic guidelines of theWorld Health Organization.'
Peripheral BMD measurements were assessed 3 times in each heel usingthe Achilles Express QUS device. Assessments wereconducted by a single investigator to avoid introducing interobserver bias. The Achilles ExpressQUS devicecombinesbroadband ultrasound attenuation and speedof sound to reducerandom measurement errors and providegreaterprecision in estimating fracture risk.Tissueattenuation was determinedby the change in ultrasound intensity measuredbetween 2 transducers! The AchillesExpresscombinesbroadbandultrasoundattenuationand speedof sound into the SI, which is then compared with age-matchedcontrols to determine at-score equivalent." The r-score equivalents are reported in thisstudy.
Statistical analyses were performed with the Minitabstatistical package, release 14 
Results
Fifty-four subjects were recruited over 7 months; however, one subject in Group 1 was excluded following a positive urine test for pregnancy,Thus, 53 subjects completed the study, with 22 subjects in Group 1 and 31 in Group 2. One subject in each group did not complete a cOXA of the spine and wrist due to contraindications. Target enrollment of 25 and 50 subjects in Groups 1 and 2, respectively, was not achieved due to logistical issues limiting enrollment during the time in which one investigator could serve as the QUS operator. These issues included conflicts in scheduling and the end of recruitment upon completion of the QUS operator's residencyprogram. The positioning precision of the device in the hands of the single operatorwas 5.6%, which is consistent with a previous study investigating QUS devices (range 1.6-7.0%). 6 Demographic data for the study participants are presented in Table 1 . In addition to the expecteddifferences in the mean age, there were significantdifferences in body mass index, past smoking history, and use of thyroid and antiresorptive drug therapies. Correlation coefficients between QUS and cOXA measurements are presented in Table 2 . Although weight has been shown to be an independent predictorof BMD as measured by QUS, post hoc analysis showed no correlation. Figure 1 illustrates the correlation of QUS of the nondominant heel with spine (la) and hip (lb) cOXA in each group of women. The figure also demonstrates the frequency of false positive and negative results as they relate to osteopenia, defined with a line of identityat a t-score of -1. Mean t-scores demonstratedfor all cOXA scans (hip, spine, wrist) as well as QUS measurements (dominant,nondominant foot) in Group 1 were significantly different (p < 0.05) from those in Group 2.
The mean ± SO cOXA t-scores in Group 1 were 0.1 ± 0.8, -0.1 ± 0.8 (n =21), and 0.6 ± 0.9 for the hip, spine, and wrist,respectively; in Group 2, they were-0.6 ± 1.2, -1.0 ± 1.3, and 0.0 ± 1.5 (n = 30) for the hip, spine, and wrist, respectively. The mean ± SD QUS t-scores in Group 1 were -0.2 ± 1.2 and -0.0 ± 1.2 for the nondominant and dominant ankles,respectively, and in Group2 were -1.1 ± 1.2 and -1.0 ± 1.3 for the nondominant and dominant ankles, respectively. Sensitivity,specificity,PPV,and NPV data are presented in Table 3 .
Discussion
Similar to previous studies comparing other QUS devices,our results show modestbut significant correlations of QUS with cDXA (r = 0.65 spine, r = 0.66 hip).6-lo The Achilles + first-generation devicedemonstrated significant correlations with cOXA of the spine, femoral neck, and trochanter (r = 0.678, 0.8, 0.7, respecrivelyj," There are numerousreasons for the lack of correlation (or discordance) found whencomparing BMD results fromQUS and cOXA devices/
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Oue to this discordance, it is important for pharmacists conducting BMD screenings to identify the sensitivity and specificity of the device to detectosteopenia in the population being screened. The results in Table 3 indicate that QUS has variable rates of sensitivity and specificity in the 2 populations studied. The Achilles Express identified postmenopausal (Group2) patients with osteopenia of the hip and spinewitha 92% and 79% sensitivity, respectively, and provided a low number of false negative results (patient having normal heel QUS but osteopenia on cOXA measurements). Otherwise stated,BMD screening in postmenopausal womenwith the Achilles Express wouldmiss approximately 1 in 10women withosteopenia at thehip and 2 in 10women withosteopenia at the spine. The specificity of 63% and 59% for the hip and spine comparisons, respectively, indicates that use of the Achilles Express may lead to a 30-40% incidenceof false positive results (patients categorized with osteopenia by QUS when cOXA does not indicate osteopenia). This couldresultin unnecessary follow-up cOXA testing. However, given the high NPV (92% at hip), pharmacists can be confident that a True negatives 
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The Annals of Pharmacotherapy • 2006May, Volume 40 • 833 negative QUS result for osteopenia in this population is truly negative for disease at the hip, which incurs considerable morbidity and mortality. While the data support the role of QUS in predicting fracture risk in females over the age of 45 years,":" concerns over its discordance with cOXA have led to recommendations regarding its use for screening this population.' The recommendations include follow-up cOXA scans for patients with QUS-determined t-scores below -1 and for patients with QUS t-scores between +1 and -1 if significant risk factors are present. An example of a screening tool to evaluate fracture risk is the Simple Calculated Osteoporosis Risk Estimation, which can be completed easily in a community pharmacy setting. 24 ,2S This tool has been studied in combination with QUS screening and has been shown to improve sensitivity at the cost of lowering specificity,"
In the young, healthy population (Group 1), the sensitivity of the Achilles Express to detect osteopenia was 100% in the spine and 80% in the hip. While 100% sensitivity and a high NPV (negative result truly negative) are encouraging, caution is warranted in interpreting these results, as few of these study participants had documented osteopenia. When the prevalence of disease is low, PPV will decrease and NPV will rise." The potential exists for a high rate of false negatives for osteopenia using QUS in a younger population because BMO measured at peripheral sites (heel, finger) may be greater than BMO measured at central sites (lumbar spine) in this population.v" In other words, a negative result with peripheral BMO in younger patients, which involves measurement of primarily cortical bone, does not rule out the existence of bone loss at central sites, which are primarily composed of trabecular bone. "n =21.
Limitations of this study include a low rate of those with r-scores indicating osteopenia and the relatively young age of participants. Thus, the correlation of the QUS device with cOXA in an older female population or those with defined osteoporosis is unknown and deserves further study. Our study had a relatively small sample size, which limited our ability to identify substantial numbers of patients positive for the disease. This can impact the PPV and NPV results obtained,"
Conclusions
Pharmacists selecting a peripheral BMO screening device should familiarize themselves with the technology available and the advantages and disadvantages of those options.t" The Achilles Express ultrasonometer is a reasonable screening tool for identifying low BMD in postmenopausal women. However, the low rate of disease in women under 35 years of age warrants caution regarding the use of this device as a screening tool to identify low BMD in a young, premenopausal population. (LDC). Los farmaceuticos de la comunidaddebenconocerla precision, la sensibilidad, y la especificidad de los dispositivos CDS antesde comprarlos.
OBJETIVO: Determinarla precision,la sensibilidad, y la especificidad del ultrason6metro AchillesExpressen comparaci6n con el absorci6metro centralde energfa dual par rayos-x(cOXA)y evaluarsu utilidadcomo dispositivo para la detecci6n de la densidad6sea en la farmacia comunitaria.
METoDOS: Se lIev6a cabo un estudioprospectivo en una farmacia comunitariay clfnicade pacientes ambulatorios en el que participaron mujeresde raza caucasicaentre las edadesde 25 a 35 afios(j6venes, saludables,grupo 1) y mujeresde raza caucasicade 45 afiosen adelante (en la posmenopausia, gropo 2). Se evalu61aOMO mediantecOXA de la muiiecano dominante,la cadera,y la vertebra. Se evalu61a OMO medianteCUS del talon,utilizando el dispositivo AchillesExpress.Las mediciones principales de los resultados fueron la correlaci6n de las puntuaciones t entreel cOXA y las mediciones del CUS utilizandola pruebade correlaci6n de Pearson. RF,sULTADOS: Se inscribieron 22 (30± 4 aiios)y 31 (55 ± 17afios) mujeres en 2 grupos,respectivamente. Se encontraron correlaciones significativas entreel CDS y las puntuaciones t mediante cOXAen lacaderay la vertebra en ambosgrupos,Loscoeficientes de la correlaci6n parael CUS en comparaci6n con el cOXAde la caderafueron 051 (95%CI 0.11a 0.77)y 0.70 (95%CI 0.46 a 0.85)en los grupos I y 2, respectivamente. Loscoeficientes de la correlaci6n parael CDSen comparaci6n con el cOXAde la vertebra fueron 0.64 (95%CI 031 a 0.84)y 0.60 (9%5CI 031 a 0.79)en losgrupos I y 2, respectivamente. EI dispositivo CUS tieneuna sensibilidad de 88% y unaespecificidad de 71% paradetectar una puntuaci6n t mediante cOXAen la caderamenorde -I. 
